GLP-1 的相關製劑 (胰島素相關的減肥針) 專利在 2023-2027 到期 ... 不知道市場接下來會有什麼變化
The patents for some GLP-1 drugs are set to expire in the coming years, including:
Victoza (liraglutide): The patent for this drug expired in late 2023, allowing companies to pursue generic versions.
Xultophy (liraglutide–insulin degludec): The patent for this drug is set to expire on November 18, 2024.
Victoza (liraglutide): The patent for this drug expired in late 2023, allowing companies to pursue generic versions.
Xultophy (liraglutide–insulin degludec): The patent for this drug is set to expire on November 18, 2024.
Trulicity: The U.S. patent for this drug is set to expire in 2027.
Semaglutide (Wegovy): The patent for this drug is set to expire on March 20, 2026. However, Novo Nordisk is working to extend its exclusivity by adding other patents.
Semaglutide (Wegovy): The patent for this drug is set to expire on March 20, 2026. However, Novo Nordisk is working to extend its exclusivity by adding other patents.
Dulaglutide - Wikipedia
Liraglutide - Wikipedia
進入大減肥時代
不過現在的劑型好像還是不太能夠方便使用 ...
Novo Nordisk 要併 CMO 大廠 Catalent 是有原因的 先堵死可以做這件事的最佳路徑
hims